Announcement from Dashenlin Pharmaceutical Group on the resignation of the board secretary and appointment of the CFO as acting board secretary.
Legal Opinion of King & Wood Mallesons (Guangzhou) Law Firm on the Third Extraordinary General Meeting of Shareholders of Dashenlin Pharmaceutical Group Co., Ltd. in 2024, Peking.
Announcement of the resolution of the third interim shareholder meeting of Dashenlin Pharmaceutical Group Co., Ltd. in 2024.
Materials for the 3rd interim shareholder meeting of Dashenlin Pharmaceutical Group Co., Ltd. in 2024.
Announcement of Dashenlin Pharmaceutical Group Co., Ltd. regarding the progress of the lawsuit involved.
Dashenlin Pharmaceutical Group Co., Ltd.'s convertible bonds have been converted to equity, and the announcement of changes in shares.
Notice of the 3rd interim shareholder meeting of Dashenlin Pharmaceutical Group Co., Ltd. to be held in 2024.
General Manager Work Regulations (Revised July 2024)
Board of directors secretary working system (revised in July 2024).
Board of directors meeting rules (Revised in July 2024)
Announcement of the Revision of the Articles of Association and Some Corporate Governance Systems of Dashenlin Pharmaceutical Group Co., Ltd.
Trustee Management Report on the Public Issuance of Convertible Corporate Bonds by Dashenlin Pharmaceutical Group Co., Ltd. (2023)
Tracking Rating Report for Convertible Corporate Bonds of Dashenlin Pharmaceutical Group Co., Ltd. due in 2024
Announcement of the tracking rating results of convertible corporate bonds due in 2024 by Dashenlin Pharmaceutical Group Co., Ltd.
Dashenlin Pharmaceutical Group Co., Ltd.'s informative notice regarding the "Improving Efficiency to Increase Returns" action plan for the year 2024.
Announcement on the Adjustment of the Conversion Price of Dashenlin Pharmaceutical Group Co., Ltd.'s "Dashen Convertible Bonds"
Announcement on the change of legal representative of Dashenlin Pharmaceutical Group Co., Ltd.
Announcement on the suspension of conversion of dashenlin convertible bonds during the implementation of the 2023 equity distribution by Dashenlin Pharmaceutical Group Co., Ltd.
Announcement of Dashenlin Pharmaceutical Group Co., Ltd. on not revising the conversion price of “Dashenlin Bonds” downward
Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders of Dashenlin Pharmaceutical Group Co., Ltd.
No Data